<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04299646</url>
  </required_header>
  <id_info>
    <org_study_id>GETUG-StORM-01</org_study_id>
    <nct_id>NCT04299646</nct_id>
  </id_info>
  <brief_title>Study Assessing Stereotactic Radiotherapy in Therapeutic Strategy of Oligoprogressive Renal Cell Carcinoma Metastases</brief_title>
  <acronym>GETUG-StORM-01</acronym>
  <official_title>A Randomized Phase II Study Assessing Stereotactic Radiotherapy in Therapeutic Strategy of Oligoprogressive Renal Cell Carcinoma Metastases</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centre Francois Baclesse</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute, France</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>GETUG</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Centre Francois Baclesse</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Every year, 12500 primary renal cell carcinoma (RCC) are diagnosed in France. Metastases&#xD;
      occur in half of RCC patients.&#xD;
&#xD;
      Management of metastatic RCC is based on systemic treatments (targeted&#xD;
      therapies/immunotherapy). However, resistance to systemic treatment is frequent. In case of&#xD;
      progression, usual therapeutic attitude is initiating another systemic therapy.&#xD;
&#xD;
      Because of the emergence of resistant tumor clonal cells, some patients progress only on few&#xD;
      sites while the rest of tumor burden is controlled. In this setting named oligoprogressive&#xD;
      disease [isolated progression of &lt;3-5 metastase(s)], ablative treatments of these evolving&#xD;
      metastatic sites could allow a disease control and a reduced risk of new metastases&#xD;
      occurrence by tumor-cell reembolization. Such strategy is challenging to prolong ongoing&#xD;
      systemic treatment and delay further lines.&#xD;
&#xD;
      Although RCC was considered radioresistant and radiotherapy with conventional fractionation&#xD;
      was mainly used for palliation of symptoms, stereotactic radiotherapy (SRT), by delivering&#xD;
      high dose in one or few fractions, allows local control for about 90% of RCC metastases&#xD;
      through various radiobiological pathways. Furthermore, some data suggest that high-dose focal&#xD;
      irradiation of RCC could induce a systemic antitumor response mediated by immunologic&#xD;
      effectors(1). This phenomenon (&quot;abscopal effect&quot;) could be enhanced in patients under&#xD;
      immunotherapy, including anti-PD1.&#xD;
&#xD;
      Several retrospective studies and one non-randomized phase-II study highly suggest the&#xD;
      interest of SRT as focal ablative treatment in RCC oligometastases with excellent local&#xD;
      control rates and low toxicity(2,3).&#xD;
&#xD;
      Furthermore, the multicentric retrospective study the sponsor recently conducted within the&#xD;
      GETUG group among 101 metastatic RCC patients with oligoprogression under systemic therapy&#xD;
      highlighted that SRT on progressive sites provided a median of 8.6-month progression-free&#xD;
      survival and allowed to continue current systemic line for 10.5 months.&#xD;
&#xD;
      However, to date, there are no prospective data assessing the interest of SRT for management&#xD;
      of oligoprogressive metastatic RCC.&#xD;
&#xD;
      The sponsor aim to prospectively evaluate the interest of SRT as a therapeutic strategy for&#xD;
      local control of oligoprogressive metastatic RCC under ongoing systemic treatment, and&#xD;
      consequently delay subsequent systemic treatment.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 1, 2020</start_date>
  <completion_date type="Anticipated">September 2023</completion_date>
  <primary_completion_date type="Anticipated">January 2023</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Randomized 2:1 phase II trial</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Progression-free survival</measure>
    <time_frame>6 months post-randomization</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of participants with treatment-related adverse events as assessed by CTCAE v4.0</measure>
    <time_frame>Until 1 month after end of treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Local control rate</measure>
    <time_frame>3, 6 and 12 months after randomization</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall control rate</measure>
    <time_frame>3, 6 and 12 months after randomization</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">114</enrollment>
  <condition>Metastatic Renal Cell Carcinoma</condition>
  <condition>Radiotherapy</condition>
  <arm_group>
    <arm_group_label>Steretactic radiotherapy plus systemic treatment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Systemic treatment</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Steretactic radiotherapy</intervention_name>
    <description>Steretactic radiotherapy</description>
    <arm_group_label>Steretactic radiotherapy plus systemic treatment</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pursuit of ongoing systemic treatment</intervention_name>
    <description>Pursuit of ongoing systemic treatment</description>
    <arm_group_label>Steretactic radiotherapy plus systemic treatment</arm_group_label>
    <arm_group_label>Systemic treatment</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Clear cell renal cancer histologically proved (association with other histologic&#xD;
             component are permitted)&#xD;
&#xD;
          -  Patients of good or intermediate prognostic, according to Heng criteria&#xD;
&#xD;
          -  Extracerebral metastatic disease documented with imagery&#xD;
&#xD;
          -  Patients treated in first or second line systemic therapy&#xD;
&#xD;
          -  Systemic treatment may be targeted therapies (tyrosine kinase inhibitors or mammalian&#xD;
             target of rapamycin inhibitors) and/or immunotherapy according to French applicable&#xD;
             standards; patients treated in a clinical trial are also eligible if allowed by trial&#xD;
             sponsor&#xD;
&#xD;
          -  Oligoprogressive disease documented with imagery, defined as the emergence or&#xD;
             progression of 1 to 3 metastases and progression localized in up to 2 organs&#xD;
&#xD;
          -  Oligoprogressive disease confirmed with 2 CT scans performed 2 months apart&#xD;
&#xD;
          -  At least one measurable progressing metastasis according to R.E.C.I.S.T. criteria v1.1&#xD;
&#xD;
          -  All oligoprogressive target lesions measuring ≤ 4 cm&#xD;
&#xD;
          -  Good general condition (WHO performance status ≤ 2)&#xD;
&#xD;
          -  All progressive lesions have to be accessible to SRT, performed concurrently or&#xD;
             sequentially&#xD;
&#xD;
          -  No contraindication to systemic therapy and stereotactic radiation therapy&#xD;
&#xD;
          -  Patients aged 18 years or older&#xD;
&#xD;
          -  Signed informed consent form&#xD;
&#xD;
          -  Patients affiliated to the social security system&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  More than 3 progressive metastases&#xD;
&#xD;
          -  Non measurable disease according R.E.C.I.S.T. criteria&#xD;
&#xD;
          -  Patients who received 3 or more lines of systemic therapy&#xD;
&#xD;
          -  Inability to treat all progressive metastatic sites with SRT&#xD;
&#xD;
          -  Previous radiation therapy performed in ≥ 1 target lesion&#xD;
&#xD;
          -  At least 1 oligoprogressive target lesion measuring &gt; 4 cm&#xD;
&#xD;
          -  Presence of brain metastases&#xD;
&#xD;
          -  Presence of ultra-central pulmonary metastasis&#xD;
&#xD;
          -  Progressing metastasis in a long bone&#xD;
&#xD;
          -  At least 1 progressive metastasis requiring surgical treatment&#xD;
&#xD;
          -  Current or past history of second neoplasm diagnosed within the last 5 years&#xD;
&#xD;
          -  Pregnancy or breast feeding or inadequate contraceptive measures&#xD;
&#xD;
          -  Patients who cannot be adequately followed up&#xD;
&#xD;
          -  Patient deprived of freedom or under guardianship&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Emmanuel MEYER, MD</last_name>
    <phone>+ 332 31 45 50 20</phone>
    <email>e.meyer@mail.baclesse.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Jean-Michel GRELLARD</last_name>
    <phone>+33 2 31 45 50 02</phone>
    <email>jm.grellard@baclesse.unicancer.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Clinique Claude Bernard</name>
      <address>
        <city>Albi</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Laurent VOTRON, MD</last_name>
    </contact>
    <investigator>
      <last_name>Laurent VOTRON, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Claude ALZIEU, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Pierre AUBERDIAC, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Yan BERGE, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Institut de Cancérologie de l'Ouest</name>
      <address>
        <city>Angers</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Jérémy COLLIAUX, MD</last_name>
    </contact>
    <investigator>
      <last_name>Jérémy COLLIAUX, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Nathalie MESGOUEZ-NEBOUT, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Hadji HAMIDOU, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Thibaut LIZEE, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Institut Bergonié</name>
      <address>
        <city>Bordeaux</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Pauline GILLON, MD</last_name>
    </contact>
    <investigator>
      <last_name>Pauline GILLON, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Radiothérapie Bordeaux Nord Aquitaine</name>
      <address>
        <city>Bordeaux</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Sigolène GALLAND-GIRODET, MD</last_name>
    </contact>
    <investigator>
      <last_name>Sigolène GALLAND-GIRODET, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>François GUICHARD, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Bénédicte HENRIQUES, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre François Baclesse</name>
      <address>
        <city>Caen</city>
        <zip>14076</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Emmanuel MEYER, MD</last_name>
      <phone>+33 2 31 45 50 20</phone>
      <email>e.meyer@mail.baclesse.fr</email>
    </contact>
    <contact_backup>
      <last_name>Jean-Michel jm.grellard@baclesse.unicancer.fr</last_name>
      <phone>+33 2 31 45 50 02</phone>
      <email>jm.grellard@baclesse.unicancer.fr</email>
    </contact_backup>
    <investigator>
      <last_name>Emmanuel MEYER, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Florence JOLY, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Pierre-Emmanuel BRACHET, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Elodie COQUAN, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre Jean Perrin</name>
      <address>
        <city>Clermont-Ferrand</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Genevieve LOOS, MD</last_name>
    </contact>
    <investigator>
      <last_name>Genevieve LOOS, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Hakim MAHAMMEDI, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jessica MIROIR, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU Henri Mondor</name>
      <address>
        <city>Créteil</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Yacid BELKACEMI, MD</last_name>
    </contact>
    <investigator>
      <last_name>Yacid BELKACEMI, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Gabriele CORAGGIO, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Institut de cancérologie de Bourgogne (Dijon, Auxerre, Chalon sur Saône)</name>
      <address>
        <city>Dijon</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Alexis LEPINOY, MD</last_name>
    </contact>
    <investigator>
      <last_name>Alexis LEPINOY, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Benjamin SCHIPMAN, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Véronique LORGIS, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Nicolas LESCUT, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre Léon Bérard</name>
      <address>
        <city>Lyon</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Naji SALEM, MD</last_name>
    </contact>
    <investigator>
      <last_name>Naji SALEM, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Gwenaëlle GRAVIS, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Cécile VICIER, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Mathilde GUERIN, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Slimane DERMECHE, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Géraldine PIGNOT, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jochen WALZ, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU La Timone</name>
      <address>
        <city>Marseille</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Xavier MURACCIOLE, MD</last_name>
    </contact>
    <investigator>
      <last_name>Xavier MURACCIOLE, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Eric LECHEVALLIER, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Gilles KARSENTY, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jean-Laurent DEVILLE, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>veronique DELAPORTE, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>ICM</name>
      <address>
        <city>Montpellier</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>David AZRIA, PhD</last_name>
    </contact>
    <investigator>
      <last_name>David AZRIA, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Marie CHARISSOUX, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Diego TOSI, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Carmen LLACER-MOSCARDO, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Marie VIALA, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Institut de Cancérologie de Lorraine</name>
      <address>
        <city>Nancy</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Anais STEFANI, MD</last_name>
    </contact>
    <investigator>
      <last_name>Anais STEFANI, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Anne-Sophie BAUMANN, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jean-François PY, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Institut de Cancérologie de l'Ouest</name>
      <address>
        <city>Nantes</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Stephane SUPIOT, MD</last_name>
    </contact>
    <investigator>
      <last_name>Stephane SUPIOT, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Valentine GUIMAS, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Vincent LIBOIS, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Emmanuel RIO, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre Haute Energie</name>
      <address>
        <city>Nice</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>René Jean BENSADOUN, PhD</last_name>
    </contact>
    <investigator>
      <last_name>René Jean BENSADOUN, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Institut Curie</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Samar Line KRHLI, MD</last_name>
    </contact>
    <investigator>
      <last_name>Samar Line KRHLI, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Gilles CREHANGE, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Mathieu MINSAT, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Thomas FREDERIC MOREAU, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Institut de Cancérologie de la Loire Lucien Neuwirth</name>
      <address>
        <city>Saint-Étienne</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Nicolas MAGNE, MD</last_name>
    </contact>
    <investigator>
      <last_name>Nicolas MAGNE, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Julien LANGRAND-ESCURE, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Alexis VALLARD, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jane-Chloé TRONE, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Grégoire PIGNE, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>IUCT</name>
      <address>
        <city>Toulouse</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Pierre GRAFF-CAILLEAUD, MD</last_name>
    </contact>
    <investigator>
      <last_name>Pierre GRAFF-CAILLEAUD, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jonathan KHALIFA, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre marie Curie</name>
      <address>
        <city>Valence</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Jean-Baptiste GUY, MD</last_name>
    </contact>
    <investigator>
      <last_name>Jean-Baptiste GUY, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Emilie BONNET, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Bertrand FLEURY, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>April 2021</verification_date>
  <study_first_submitted>March 2, 2020</study_first_submitted>
  <study_first_submitted_qc>March 6, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">March 9, 2020</study_first_posted>
  <last_update_submitted>April 2, 2021</last_update_submitted>
  <last_update_submitted_qc>April 2, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 5, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Carcinoma, Renal Cell</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

